Roca Therapeutics completes seed funding round
September 22, 2022 01:00 ET
|
Roca Therapeutics
Roca Therapeutics completes seed funding round Series A funding round initiated to further fund the clinical development of its "First In Class" small molecules against Uveal Melanoma and other...
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
June 08, 2022 07:00 ET
|
Immunocore Holdings Limited
The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable...
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved in the United States and European Union for the treatment of unresectable...
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
April 04, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only treatment approved in the E.U. to...
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
March 03, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic...
Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
March 02, 2022 08:37 ET
|
Hillstream BioPharma Inc.
HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the...
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
February 25, 2022 02:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency,...
Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
February 16, 2022 09:40 ET
|
Hillstream BioPharma Inc.
-Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates ferroptosis, an emerging iron-mediated cell...
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
January 26, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only FDA approved therapy for the treatment of...
Delcath Systems Closes $22.0 Million Public Offering of Common Stock
May 05, 2020 16:05 ET
|
Delcath Systems, Inc.
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...